Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Analyst Ratings and Price Targets for Doximity NYSE DOCS

Elaine Mendonca by Elaine Mendonca
March 15, 2024
in Breaking News
0
Finance_ stocks to buy
0
SHARES
5
VIEWS
Share on FacebookShare on Twitter

The latest data on Doximity (NYSE: DOCS) from the past quarter reveals a diverse range of opinions from analysts, ranging from bullish to bearish. Here is a breakdown of their recent ratings and any changes over the last 30 days compared to previous months:

– Total Ratings: Bullish (0), Somewhat Bullish (0), Indifferent (5), Somewhat Bearish (1), Bearish (0)
– Last 30 Days: Bullish (0), Somewhat Bullish (0), Indifferent (0), Somewhat Bearish (1), Bearish (0)
– 1 Month Ago: Bullish (0), Somewhat Bullish (0), Indifferent (1), Somewhat Bearish (0), Bearish (0)
– 2 Months Ago: Bullish (0), Somewhat Bullish (0), Indifferent (3), Somewhat Bearish (0), Bearish (0)
– 3 Months Ago: Bullish (0), Somewhat Bullish (0), Indifferent (1), Somewhat Bearish (0), Bearish (0)

Analysts have also provided 12-month price targets for Doximity, with an average target of $29.00, a high estimate of $32.00, and a low estimate of $25.00. This suggests a positive trend, with the current average target indicating a 16.0% increase from the previous average price target of $25.00.

Key actions from analysts include upgrades and changes in ratings, such as:

– Anne Samuel from JP Morgan upgraded the rating to Underweight with a price target of $25.00, up from $22.00.
– Michael Cherny at Leerink Partners initiated a Market Perform rating with a price target of $32.00.
– Jailendra Singh from Truist Securities upgraded the rating to Hold with a price target of $29.00, up from $28.00.
– Stan Berenshteyn at Wells Fargo upgraded the rating to Equal-Weight with a price target of $27.00, up from $25.00.
– Allen Lutz from B of A Securities upgraded the rating to Neutral with a price target of $32.00, up from $29.00.
– Allen Lutz from B of A Securities also upgraded the rating to Neutral with a price target of $29.00, up from $21.00.

These changes in ratings reflect analysts’ responses to market conditions and company performance, indicating adjustments in their recommendations based on recent developments.

DOCS Stock Shows Positive Momentum on March 15, 2024: Trading Above 200-Day Moving Average

On March 15, 2024, DOCS stock showed positive momentum as it traded in the middle of its 52-week range and above its 200-day simple moving average. The price of DOCS shares increased by $0.20 since the market last closed, representing a 0.72% rise. The stock opened at $27.76, which was $0.09 lower than its previous close. Overall, DOCS stock had a decent performance on March 15, 2024, with a slight increase in price and trading above its 200-day moving average. Investors will be keeping a close eye on the stock in the coming days to see if this positive momentum continues.

DOCS Stock Performance Analysis: Revenue Growth but Decline in Net Income

On March 15, 2024, investors were closely monitoring the stock performance of DOCS, a company that provides document management solutions. According to data from CNN Money, DOCS reported a total revenue of $419.05 million for the past year, which represented a 21.98% increase compared to the previous year. In the third quarter of the same year, the company generated $135.28 million in total revenue, marking a 19.08% increase from the previous quarter.

Despite the positive revenue growth, DOCS experienced a decline in net income over the past year. The company reported a net income of $112.82 million for the year, which represented a 15.34% decrease compared to the previous year. However, in the third quarter, DOCS saw a significant improvement in net income, with a reported figure of $47.96 million, marking a 56.71% increase from the previous quarter.

Earnings per share (EPS) also showed mixed results for DOCS. The company reported an EPS of $0.53 for the past year, which represented a 24.15% decrease compared to the previous year. However, in the third quarter, DOCS reported an EPS of $0.24, marking a substantial 63.39% increase from the previous quarter.

Overall, the stock performance of DOCS on March 15, 2024, reflected a mix of positive and negative indicators. Investors will continue to monitor the financial performance of DOCS closely to assess the company’s future prospects and potential for growth in the document management solutions industry.

Tags: DOCS
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
OHI stock news

Olin Announces Dividend Payout and Maintains Consistent Dividend History

Westinghouse Air Brake CEOs Insider Sell Causes Share Price Dip

Analyst Increases Price Target for Madrigal Pharmaceuticals Maintains Strong Buy Recommendation

Recommended

Super Micro Computer Stock

Super Micro Stock Surges Amid AI Infrastructure Boom

4 months ago
Adobe Stock

Adobe’s AI Ambitions Face Investor Skepticism

4 months ago
IBM Stock

Strong IBM Earnings Fail to Impress Market as Key Segment Shows Weakness

4 months ago
Inozyme Pharma Inc Stock

Inozyme Pharma Acquisition Finalized: Strategic Focus Shifts to Clinical Development

5 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Myers Industries Set to Report Full-Year and Q4 2025 Results

OneSpan Strengthens Mobile Security Arsenal with Strategic Acquisition

Riley Exploration Permian Bolsters Board with Industry Veteran Amid Shareholder Activity

Great Lakes Dredge & Dock: A Cash Flow Inflection Point Approaches

Investors Await March Report for Boston Omaha’s Strategic Direction

Universal Insurance Maintains Quarterly Payout Amid Sector Headwinds

Trending

Orthofix Medical Stock
Earnings

Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio

by Rodolfo Hanigan
February 7, 2026
0

Investor attention turns to Orthofix Medical as the company bolsters the clinical support for its biologics business...

CrossFirst Bankshares Stock

A New Chapter for First Busey as CrossFirst Merger Finalizes

February 7, 2026
Golden Entertainment Stock

Golden Entertainment to Exit Public Markets in Strategic Privatization Deal

February 7, 2026
Myers Industries Stock

Myers Industries Set to Report Full-Year and Q4 2025 Results

February 7, 2026
OneSpan Stock

OneSpan Strengthens Mobile Security Arsenal with Strategic Acquisition

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio
  • A New Chapter for First Busey as CrossFirst Merger Finalizes
  • Golden Entertainment to Exit Public Markets in Strategic Privatization Deal

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com